following an abbreviated submission:
cabozantinib (Cabozantinib Ipsen) is accepted for use within NHSScotland.
Indication under review: as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.
Cabozantinib offers an additional treatment choice in the therapeutic class of protein kinase inhibitors.
Another protein kinase inhibitor was accepted for use under the end of life process.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice272KB (PDF)
Medicine details
- Medicine name:
- cabozantinib (Cabozantinib Ipsen)
- SMC ID:
- SMC2754
- Indication:
As monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.
- Pharmaceutical company
- Ipsen Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 10 March 2025